Special Issue "Zika Virus: Therapeutic Advances"
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: closed (30 April 2020).
Interests: Flavivirus; zoonosis; virus-host interactions; antivirals; vaccines; Coronavirus
Special Issues and Collections in MDPI journals
When the Zika virus (ZIKV) was first discovered in Africa in 1947, it was considered responsible for an almost negligible disease, since its infection was usually asymptomatic or produced a relatively mild illness followed by an uneventful recovery. However, after its spread in Asia in the 1980s, its subsequent outbreaks in Micronesia and French Polynesia in this century, and its recent introduction in the Americas, ZIKV now constitutes a threat to global health, causing a great social and sanitary alarm due to its association with severe neurological and ophthalmological complications. Currently, no specific vaccines or antiviral therapies against ZIKV are available, and treatments are palliative and mainly directed to symptoms relief. Nevertheless, a great effort has been made lately to search for efficient therapeutic tools (antivirals and vaccines) and to understand the involved molecular mechanisms.
To achieve a more comprehensive understanding of the current trends in the development of new therapeutic approaches, the journal Pharmaceuticals now invites valuable contributions that report original observations or reviews on this matter.
Dr. Juan-Carlos Saiz
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Zika virus
- virus-host cell interactions